. 2013 Jun;131(6):e1897–e1907. doi: 10.1542/peds.2013-0072

TABLE 3.

Strength of Evidence of Hormonal Treatments for Cryptorchidism

No. of Studies; Total Subjects; Testes Treated	Risk of Bias	Consistency	Directness	Precision	Strength of Evidence and Magnitude of Effect
Testicular descent
LHRH versus placebo 6; 752; 935	RCTs/Moderate	Consistent	Direct	Imprecise	Moderate LHRH: 9%–62%
LHRH versus placebo 6; 752; 935	RCTs/Moderate	Consistent	Direct	Imprecise	Placebo: 0%–18%
hCG versus placebo 1; 243; 280	RCT/Moderate	Unknown	Direct	Unknown	Low Bilateral: 23% vs 0%
hCG versus placebo 1; 243; 280	RCT/Moderate	Unknown	Direct	Unknown	Unilateral: 15% vs 0%
LHRH versus hCG 3; 431; 465	RCT/Low	Inconsistent	Direct	Imprecise	Low RCT:
					LHRH: 0%–18.8%
					hCG: 5.9%–23.0%
LHRH versus hCG 1; 324; 198	Cohort/High	Consistent	Direct	Imprecise	Cohort:
					LHRH: 29.4%
					hCG: 34.5%

hCG human chorionic gonadotropin; LHRH Luteinizing-hormone-releasing hormone; RCT randomized controlled trial.